Using a mouse model, scientists from the RIKEN-Max Planck Joint Research Center for Systems Chemical Biology and a number of other institutes have identified a sugar molecule that reduced the inflammatory response and progress of emphysema, a common component of chronic obstructive pulmonary disease (COPD). According to Naoyuki Taniguchi, the leader of the group, this discovery could lead to the development of drugs based on glycans—biological sugar molecules—for the treatment of diseases such as COPD, which is the fourth leading cause of death worldwide.
As part of the research group’s work to explore the roles of sugar molecules in health and disease, they found that keratan sulfate, a large negatively charged saccharide found in the small airway of the lung, is decreased in mice that have been exposed to cigarette smoke. They wondered if this decrease might be associated with the damage that smoking causes to the lung. Taniguchi says, “We are not absolutely sure of the mechanism through which smoking leads to a reduction in keratan sulfate, but felt that clearly the reduction is important in thinking about glycan-based strategies for combating emphysema and COPD.”
They wondered whether the keratan sulfate might be playing a protective role in COPD. To test the hypothesis, they prepared a repeating disaccharide element of keratan sulfate, named L4, and administered it into two mouse models of emphysema—one a model of emphysema triggered by the enzyme elastase, and the other an exacerbation of smoking-induced emphysema triggered by LPS, a toxin found in bacterial cell walls.
In the first model, they found that that treatment with L4 prevented destruction of the alveoli—the small air sacs in lungs that are used to exchange gases, and in addition that it reduced the infiltration of a type of white blood cell called neutrophils, which is symptomatic of an inflammatory response, as well as levels of inflammatory cytokines and tissue-degrading enzymes. Although L4 was shown to inhibit these enzymes, they did not find any ability of L4 to directly reduce the production of cytokines or reactive oxygen species, so concluded that the action was also being done indirectly, through mechanisms involving the neutrophils.
In the exacerbation model, they found that the L4 administration prevented the influx of neutrophils. According to Taniguchi, “We found that L4 was as effective as dexamethasone in reducing neutrophil infiltration. This is very exciting, because dexamethasone, the treatment currently used for COPD, is a steroid medication that can have serious side effects and can in some cases make the outcome worse. It will be exciting if we can show that L4—a sugar molecule which we found had no adverse effects in the mice even at high doses—can be used as a treatment for this condition, which exerts a tremendous health burden.”
According to Taniguchi, there is still work to be done in the area. “We plan now to try to determine exactly how L4 blocks neutrophil migration, by finding a target receptor protein, and how L4 can suppress inflammation in vivo, as this could give us important insights into the mechanism of COPD progression and how it can be halted.”
Receive an email update when we add a new COPD article.
The Latest on: COPD
via Google News
The Latest on: COPD
- Pulmonary tuberculosis in COPD may increase risk of lung canceron October 14, 2021 at 8:30 pm
The studies of pulmonary tuberculosis (PTB) affecting lung cancer development in chronic obstructive pulmonary disease (COPD) patients is limited. A new study by Dr Hye Yun Park MD and team ...
- Does Implementation of a Pulmonary Embolism Diagnostic Strategy Yield Benefits in COPD?on October 14, 2021 at 12:02 pm
Researchers in Spain investigated whether implementation of a pulmonary embolism diagnostic strategy improved outcomes among patients with chronic obstructive pulmonary disease (COPD).
- What is COPD and who is at risk of getting the lung condition?on October 13, 2021 at 6:23 am
IF you’re suffering with increased breathlessness and a persistent chesty cough with phlegm then you might have a lung condition. Chronic obstructive pulmonary disease (COPD) refers to a ...
- Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021on October 12, 2021 at 11:00 pm
Bronchodilation demonstrated with pMDI, consistent with DPI and nebulizer formulationsLONDON and RALEIGH, N.C., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a ...
- Simple, Low-Cost Tests Can Help Diagnose COPD in China, Study Showson October 12, 2021 at 6:53 am
The study found that a combination of the Chinese symptom-based questionnaire and microspirometry could provide the most efficient and cost-effective way of identifying patients who need treatment for ...
- Growth in Population of Active Smokers Expected to Drive Global COPD and Asthma Diagnostic and Monitoring Market: Ken Researchon October 12, 2021 at 6:49 am
The COPD and asthma diagnostic & monitoring devices are used for the assessing, diagnosing and treating the patients of lung diseases such as COPD and asthma. As the lung function weakens with age, ...
- When Living with COPD, nebulized maintenance therapy may be an appropriate optionon October 11, 2021 at 11:19 am
For individuals living with COPD, small changes may make a difference. Byline: Viatris Inc. and Theravance Biopharma US, Inc. COPD, or chronic obstructive pulmonary disease, is a group of ...
- Early diagnosis of COPD to be helped by simple, low cost testson October 11, 2021 at 6:34 am
New research has shown that a simple questionnaire and airflow measurement test can help diagnose chronic obstructive pulmo ...
- COPD and the Workplace: Know the Risks and Take Actionon October 8, 2021 at 4:15 pm
Among the millions of Americans with COPD, or chronic obstructive pulmonary disease, most can point to smoking as the ...
via Bing News